+

WO2018190896A1 - Compositions de peptides mimétiques de l'apoe - Google Patents

Compositions de peptides mimétiques de l'apoe Download PDF

Info

Publication number
WO2018190896A1
WO2018190896A1 PCT/US2017/041663 US2017041663W WO2018190896A1 WO 2018190896 A1 WO2018190896 A1 WO 2018190896A1 US 2017041663 W US2017041663 W US 2017041663W WO 2018190896 A1 WO2018190896 A1 WO 2018190896A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
aqueous pharmaceutical
fatty acid
acid ester
polyoxyethylene sorbitan
Prior art date
Application number
PCT/US2017/041663
Other languages
English (en)
Inventor
Dennis I. Goldberg
Phillip M. Friden
Original Assignee
Lipimetix Development, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipimetix Development, Inc. filed Critical Lipimetix Development, Inc.
Publication of WO2018190896A1 publication Critical patent/WO2018190896A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Definitions

  • Apolipoprotein E plays an important role in the metabolism of triglyceride rich lipoproteins, such as very low density lipoprotein (VLDL) and chylomicrons.
  • VLDL very low density lipoprotein
  • chylomicrons triglyceride rich lipoproteins
  • Apolipoprotein E mediates the high affinity binding of apo E-containing lipoproteins to the low density lipoprotein (LDL) receptor (apo B, E receptor) and the members of its gene family, including LDL receptor related protein (LRP), very low density lipoprotein receptor (VLDLR) and the apoE2 receptor (apoE2R) (Mahley, R. W., (1988) Science 240, 622-630).
  • LRP low density lipoprotein
  • VLDLR very low density lipoprotein receptor
  • apoE2R apoE2 receptor
  • Atherosclerosis have been previously described. See e.g., U.S. Patent No. 6,506,880, WO 2009/032702, and Ac-hel8A-NH 2 (AEM-28), Ac-[R]hel8A-NH2 (AEM-28(R)), and Aha- [R]hE18A-NH 2 (AES-21) in U.S. Provisional Application Serial No. 62/031,585. While these peptides reduced plasma cholesterol, attaching longer chain alkyl groups to the receptor binding portion was found to improve efficacy.
  • compositions comprising longer alkyl-chain mimetic ApoE peptides such as AEM-28-14 and AEM-28-08 together with a polyoxyethylene sorbitan fatty acid exhibit no adverse effects and elicit superior reductions in plasma cholesterol.
  • AEM-28-14 formulated in 0.8% polysorbate 80 e.g., TweenTM 80
  • AEM-28-08 formulated in 0.8% polysorbate 80 (e.g., TweenTM 80) at a dose of 4 mg/kg showed a decrease of total cholesterol to 9% of baseline. See e.g., Figure 1 and Example 4.
  • FIG. 1 illustrates the change in cholesterol (mg/dL) vs time for AEM-28-08
  • FIG. 2 illustrates the change in cholesterol (mg/dL) vs time for AEM-28-08
  • AEM-28-14, and AEM-28 at concentrations of 1 or 2 mg/kg, where a) represents total cholesterol and b) represents percent (%) change in total cholesterol.
  • FIG. 3 shows the effect of AEM-28-14 in 2% Tween® 20/PBS in
  • hypercholesterolemic cynomolgus monkeys hypercholesterolemic cynomolgus monkeys.
  • aqueous formulations comprising i) a synthetic apolipoprotein E (ApoE)-mimicking peptide and ii) a polyethylene sorbitan ester.
  • aqueous pharmaceutical compositions comprising i) a synthetic apolipoprotein E (ApoE) mimicking peptide of the formula CH 3 (CH 2 ) X C(0)-LRRLRRRLLR-DWLKAFYDKVAEKLKEAF-NH 2 wherein x is an integer from 1 to 20; or a pharmaceutically acceptable salt thereof; and ii) a polyethylene sorbitan ester.
  • ApoE synthetic apolipoprotein E
  • Ac-hE18A-NH 2 used interchangeably with AEM-28, refers to the synthetic apolipoprotein E (ApoE)-mimicking peptide having the structure H 3 C(CO)-LRKLRKRLLR- DWLKAFYDKVAEKLKEAF-NH 2 .
  • Myr[R]hE18A-NH 2 used interchangeably with AEM-28-14, refers to the synthetic apolipoprotein E (ApoE)-mimicking peptide having the structure
  • Octa[R]hE18A-NH 2 used interchangeably with AEM-28-08 or AEM-28-8, refers to the synthetic apolipoprotein E (ApoE)-mimicking peptide having the structure
  • Myr refers to myristoyl, i.e., CH 3 (CH 2 )i 2 C(0)-.
  • Oxida refers to myristoyl, i.e., CH 3 (CH 2 ) 6 C(0)-.
  • the disclosed Apo E mimicking peptides disclosed herein comprise amino acids that contain basic groups (e.g., -NH 2 ) and acid groups (e.g., -COOH).
  • the basic groups can be protonated when the Apo E mimicking peptides are dissolved in an acidic aqueous solution; and the acid group can be deprotonated when the Apo E mimicking peptides are dissolved in basic solution.
  • “Pharmaceutically acceptable salt thereof refers to Apo E mimicking peptides that have been obtained from such solutions which contain acids or bases that are suitable for pharmaceutical use, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, sulfuric, acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p- toluenesulfonic, and tartaric acids.
  • acids or bases that are suitable for pharmaceutical use, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, sulfuric, acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic,
  • Suitable pharmaceutically acceptable basic salts include e.g., ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts). Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, PA, 1990, p 1445, the disclosure of which is hereby incorporated by reference.
  • polyethylene sorbitan fatty acid esters are amphipathic, nonionic surfactants composed of fatty acid esters of polyoxyethylene sorbitan.
  • fatty acid ester of polyoxyethylene sorbitan refers to a mixture of fatty acid esters of polyoxyethylene sorbitan, such as a mixture of fatty acid esters of polyoxyethylene comprising primarily sorbitan polyoxyethylene (20) sorbitan monolaurate or sorbitan polyoxyethylene (20) sorbitan oleic acid (e.g., at least 50% w/w, 60% w/w, 70% w/w, 80% w/w or 90% w/w).
  • polysorbate 20 comprising polyoxyethylene (20) sorbitan monolaurate
  • TweenTM 20 comprised of e.g., a polyethylene sorbitan ester with a calculated molecular weight of 1,225 daltons, assuming 20 ethylene oxide units, 1 sorbitol, and 1 lauric acid as the primary fatty acid
  • polysorbate 40 comprising
  • polyoxyethylene (20) sorbitan monopalmitate such as e.g., TweenTM 40
  • polysorbate 60 comprising polyoxyethylene (20) sorbitan monostearate
  • polysorbate 80 comprising polyoxyethylene (20) sorbitan monooleate
  • TweenTM 80 comprised of e.g., polyethylene sorbitan ester with a calculated molecular weight of 1,310 daltons, assuming 20 ethylene oxide units, 1 sorbitol, and 1 oleic acid as the primary fatty acid. Examples include TweenTM 80.
  • No observed adverse effect level refers to the highest tested dose of a peptide described in the compositons herein at which there is no biologically or statistically significant (e.g. alteration of morphology, functional capacity, growth, development or life span) increase in the frequency or severity of any adverse effects in the exposed subject when compared to a control subject or group.
  • the maximum tolerated dose is the highest dose of a drug (e.g., a composition as described herein) or treatment that does not cause unacceptable side effects.
  • Dose or “dosage” as used herein refers to a specific quantity of a therapeutic agent, such as an Apo E mimetic, that is taken at specific times.
  • average particle size means the average size of particles relative to the total amount the same particles in solution.
  • an effective amount is meant to mean a sufficient amount of the composition or Apo E mimetic to provide the desired effect.
  • an effective amount of an Apo E mimetic can be an amount that provides a therapeutic affect and provides sustained therapeutic effects after withdrawal of the treatment.
  • An effective amount of an Apo E mimetic is an amount that is able to cause a benefit illustrated by a decrease in atherosclerosis, a decrease in artery wall stiffness, a decrease in isolated systolic
  • hypertension a decrease in arterial inflammation, an increase in anti-oxidant capability of the HDL fraction and/or an improvement in myocardial function, as well as an amount that allows for a sustained therapeutic effect after withdrawal of the Apo E mimetic.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of disease (or underlying genetic defect) that is being treated, the particular compound used, its mode of administration, and the like. Thus, it is not possible to specify an exact “effective amount.” However, an appropriate "effective amount” may be determined by one of ordinary skill in the art using only routine experimentation.
  • sample is meant to mean an animal; a tissue or organ from an animal; a cell (either within a subject, taken directly from a subject, or a cell maintained in culture or from a cultured cell line); a cell lysate (or lysate fraction) or cell extract; or a solution containing one or more molecules derived from a cell or cellular material (e.g. a polypeptide or nucleic acid), which is assayed as described herein.
  • a sample may also be any body fluid or excretion (for example, but not limited to, blood, urine, stool, saliva, tears, bile) that contains cells or cell components.
  • subject refers to the target of administration, e.g. an animal.
  • the subject of the disclosed methods can be a vertebrate, such as a mammal.
  • the subject can be a human.
  • the term does not denote a particular age or sex.
  • Subject can be used interchangeably with “individual” or “patient”.
  • module is meant to mean to alter, by increasing or decreasing.
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment may be administered after one or more symptoms have developed, i.e., therapeutic treatment.
  • treatment may be administered in the absence of symptoms.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors), i.e., to reduce the likelihood of developing.
  • Susceptile individual being one who is at risk of developing one or more of the conditions recited herein.
  • lipoprotein or lipoproteins
  • lipoproteins is meant to mean a biochemical assembly that contains both proteins and lipids.
  • the lipids or their derivatives may be covalently or non-covalently bound to the proteins.
  • Many enzymes, transporters, structural proteins, antigens, adhesins, and toxins are lipoproteins. Examples include the high density and low density lipoproteins of the blood, the transmembrane proteins of the mitochondrion and the chloroplast, and bacterial lipoproteins
  • high-density lipoprotein is meant to mean a class of lipoproteins, varying somewhat in their size (8- 11 nm in diameter), that can transport cholesterol.
  • HDL cholesterol is cholesterol that is associated with HDLs. About one-fourth to one-third of blood cholesterol is carried by high-density lipoprotein (HDL).
  • HDL cholesterol is known as "good” cholesterol, because high levels of HDL seem to protect against heart attack.
  • Low levels of HDL (less than 40 mg/dL in men and less than 50 mg/dL in women) also increase the risk of heart disease. Medical experts think that HDL tends to carry cholesterol away from the arteries and back to the liver, where it is passed from the body.
  • VLDL very Low Density Lipoproteins
  • LDL low density lipoprotein
  • low-density lipoprotein or “LDL” is meant to mean a lipoprotein that varies in size (approx. 22 nm) and can contain a changing number of triglycerides and cholesteryl esters they actually have a mass and size distribution.
  • Each native LDL particle contains a single apolipoproteinB-100 molecule (Apo B-100, a protein with 4536 amino acid amino acid residues) and a phospholipid coat that circles the triglycerides and cholesteryl esters, keeping them soluble in the aqueous environment.
  • LDL is commonly referred to as bad cholesterol.
  • LDL cholesterol is cholesterol that is associated with LDLs.
  • LDL cholesterol When too much LDL cholesterol circulates in the blood, it can slowly build up in the inner walls of the arteries that feed the heart and brain. Together with other substances, it can form plaque, a thick, hard deposit that can narrow the arteries and make them less flexible. This condition is known as atherosclerosis. If a clot forms and blocks a narrowed artery, then heart attack or stroke can result.
  • lipid disorder is meant to mean when a subject has an excess of lipids or increased inflammatory lipids in their blood.
  • Lipids include, but are not limited to lipids such as ox-LDL (i.e., oxidized PAPC (1-palmitoyl 2-arachidonyl phophyatidyl choline). Oxidation of PAPC or PLPC, the lipid components of LDL, produce oxidized lipids. Having a lipid disorder can make you more likely to develop inflammatory disease such as atherosclerosis and hear disease. Lipid disorders can be caused by genetic predispositions or diet.
  • Lipid disorders include e.g., coronary artery disease, rheumatoid arthritis, diabetes, Alzheimer's disease, peripheral arterial disease (PAD), cerebral vascular disease, diabetes-derived cardiovascular diseases, macular degeneration, congestive heart failure, and systemic lupus.
  • coronary artery disease rheumatoid arthritis
  • diabetes Alzheimer's disease
  • peripheral arterial disease PAD
  • cerebral vascular disease diabetes-derived cardiovascular diseases
  • macular degeneration congestive heart failure
  • congestive heart failure and systemic lupus.
  • aqueous pharmaceutical compositions comprising i) a synthetic apolipoprotein E (ApoE) mimicking peptide of the formula CH 3 (CH 2 ) x C(0)-LRRLRRRLLR-DWLKAFYDKVAEKLKEAF-NH 2 , wherein x is an integer from 1 to 20; or a pharmaceutically acceptable salt thereof; and ii) a polyoxyethylene sorbitan fatty acid ester.
  • ApoE synthetic apolipoprotein E
  • x in the peptides described herein is an integer from 3 to 18, wherein the remaining features are as described in the first embodiment.
  • x is 4 to 16, wherein the remaining features are as described in the first embodiment.
  • x is 5 to 14, wherein the remaining features are as described in the first embodiment.
  • x is 5 to 13, wherein the remaining features are as described in the first embodiment.
  • x is 6 to 12, wherein the remaining features are as described in the first embodiment.
  • the ApoE mimicking peptide in the aqueous compositions described herein is of the formula CH 3 (CH 2 )i 2 C(0)-LRRLRRRLLR- DWLKAFYDKVAEKLKEAF-NH 2 , or a pharmaceutically acceptable salt thereof.
  • compositions described herein is of the formula CH 3 (CH 2 )6C(0)-LRRLRRRLLR- DWLKAFYDKVAEKLKEAF-NH 2 , or a pharmaceutically acceptable salt thereof.
  • the aqueous pharmaceutical composition comprises sterile water for injection (WFI), saline, or phosphate-buffered saline (PBS), or a combination thereof, wherein the remaining features are as described in the first, second, third, or fourth embodiment.
  • WFI sterile water for injection
  • PBS phosphate-buffered saline
  • the ApoE mimicking peptide and polyoxyethylene sorbitan fatty acid ester form particles, wherein the remaining features are as described in the first, second, third, fourth, or fifth embodiment.
  • the ApoE mimicking peptide and polyoxyethylene sorbitan fatty acid ester form particles having an average particle size of less than 20 nm, wherein the remaining features are as described in the first, second, third, fourth, fifth, or sixth embodiment.
  • the ApoE mimicking peptide and polyoxyethylene sorbitan fatty acid ester form particles having an average particle size ranging from 2 nm to 17 nm, wherein the remaining features are as described in the first, second, third, fourth, fifth, or sixth embodiment.
  • the ApoE mimicking peptide and polyoxyethylene sorbitan fatty acid ester form particles having an average particle size ranging from 5 nm to 16 nm, wherein the remaining features are as described in the first, second, third, fourth, fifth, or sixth embodiment.
  • the ApoE mimicking peptide and polyoxyethylene sorbitan fatty acid ester form particles having an average particle size ranging from 5 nm to 16 nm, wherein the remaining features are as described in the first, second, third, fourth, fifth, or sixth embodiment.
  • polyoxyethylene sorbitan fatty acid ester form particles having an average particle size ranging from 5 nm to 15 nm, wherein the remaining features are as described in the first, second, third, fourth, fifth, or sixth embodiment.
  • the ApoE mimicking peptide and polyoxyethylene sorbitan fatty acid ester form particles having an average particle size ranging from 8 nm to 16 nm, wherein the remaining features are as described in the first, second, third, fourth, fifth, or sixth embodiment.
  • the ApoE mimicking peptide and polyoxyethylene sorbitan fatty acid ester form particles having an average particle size ranging from 5 nm to 12 nm, wherein the remaining features are as described in the first, second, third, fourth, fifth, or sixth embodiment.
  • the ApoE mimicking peptide and polyoxyethylene sorbitan fatty acid ester form particles having an average particle size ranging from 6 nm to 10 nm, wherein the remaining features are as described in the first, second, third, fourth, fifth, or sixth
  • the ApoE mimicking peptide and polyoxyethylene sorbitan fatty acid ester form particles having an average particle size ranging from 7 nm to 9 nm, wherein the remaining features are as described in the first, second, third, fourth, fifth, or sixth embodiment.
  • the ApoE mimicking peptide and polyoxyethylene sorbitan fatty acid ester form particles that are micelles, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, or seventh embodiment.
  • the ApoE mimicking peptide and polyoxyethylene sorbitan fatty acid ester form particles that are micelles, which are homogenously distributed throughout the aqueous formulation, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, or eighth embodiment.
  • polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein is less than 0.200, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the molar ratio of ApoE mimicking peptide to polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein is less than or equal to 0.170, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the molar ratio of ApoE mimicking peptide to polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein is less than 0.165, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the molar ratio of ApoE mimicking peptide to polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein ranges from 0.010 to 0.170, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the molar ratio of ApoE mimicking peptide to polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein ranges from 0.020 to 0.170, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the molar ratio of ApoE mimicking peptide to polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein ranges from 0.030 to 0.170, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the molar ratio of ApoE mimicking peptide to polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein ranges from 0.050 to 0.170, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the molar ratio of ApoE mimicking peptide to polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein ranges from 0.080 to 0.170, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the molar ratio of ApoE mimicking peptide to polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein ranges from 0.010 to 0.050, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the molar ratio of ApoE mimicking peptide to polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein ranges from 0.013 to 0.020, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the molar ratio of ApoE mimicking peptide to polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein ranges from 0.014 to 0.019, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the molar ratio of ApoE mimicking peptide to polyoxyethylene sorbitan fatty acid ester in the aqueous compositions described herein is less than 0.320 (e.g., between 0.05 to 0.319), wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
  • the polyoxyethylene sorbitan fatty acid ester is selected from polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment.
  • the polyoxyethylene sorbitan fatty acid ester is polysorbate 20 or polysorbate 80, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment.
  • polyoxyethylene sorbitan fatty acid ester is polysorbate 80, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment.
  • polyoxyethylene sorbitan fatty acid ester is polysorbate 20, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment.
  • the ApoE mimicking peptide, or pharmaceutically acceptable salt thereof is present at a concentration ranging from 0.1 mg/mL to 10 mg/mL, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or eleventh embodiment.
  • the ApoE mimicking peptide, or pharmaceutically acceptable salt thereof is present at a concentration ranging from 0.8 mg/mL to 5.5 mg/mL, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or eleventh embodiment.
  • the ApoE mimicking peptide, or pharmaceutically acceptable salt thereof is present at a concentration of 1 mg/mL, 2.5 mg/mL, or 5 mg/mL, wherein the remaining features are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or eleventh embodiment.
  • compositions including independent components of the peptides and/or phospholipids described herein, are provided in the EXEMPLIFICATION.
  • the compositions described herein encompasses all of the disclosed peptides and phospholipids, and combinations and variations thereof, as further set fourth in the EXEMPLIFICATION.
  • compositions comprising i) a synthetic apolipoprotein E(ApoE)- mimicking peptide of the formula CH 3 (CH 2 ) x C(0)-LRRLRRRLLR- DWLKAFYDKVAEKLKEAF-NH 2 , wherein x is an integer from 1 to 20; or a
  • the plasma LDL, plasma VLDL, or both are affected.
  • binding of LDL to a cell of the subject is enhanced.
  • degradation of LDL by a cell of the subject is increased.
  • LDL cholesterol in the subject is lowered.
  • binding of VLDL to a cell of the subject is enhanced.
  • degradation of VLDL by a cell of the subject is increased.
  • VLDL cholesterol in the subject is lowered.
  • total plasma concentration of cholesterol in the subject is lowered.
  • the disclosed synthetic apolipoprotein E (ApoE)-mimicking peptides are administered in an amount of about 0.01 mg/kg to about 20 mg/kg, e.g., 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 mg/kg, or any range in between.
  • Also disclosed herein are methods of treating atherosclerosis comprising administering to a subject in need thereof i) a synthetic apolipoprotein E(ApoE)-mimicking peptide having the formula CH 3 (CH 2 ) X C(0)-LRRLRRRLLR-DWLKAFYDKVAEKLKEAF- NH 2 , wherein x is an integer from 1 to 20; or a pharmaceutically acceptable salt thereof; and ii) a phospholipid as described herein.
  • a synthetic apolipoprotein E(ApoE)-mimicking peptide having the formula CH 3 (CH 2 ) X C(0)-LRRLRRRLLR-DWLKAFYDKVAEKLKEAF- NH 2 , wherein x is an integer from 1 to 20; or a pharmaceutically acceptable salt thereof; and ii) a phospholipid as described herein.
  • the disclosed synthetic apolipoprotein E (ApoE) -mimicking peptides are administered in an amount of about 0.01 mg/kg to about 20 mg/kg, e.g., 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 mg/kg, or any range in between.
  • Also disclosed are methods of treating a subject with a lipid disorder comprising administering to a subject in need thereof i) a synthetic apolipoprotein E(ApoE)-mimicking peptide having the formula CH 3 (CH 2 ) X C(0)-LRRLRRRLLR-DWLKAFYDKVAEKLKEAF- NH 2 , wherein x is an integer from 1 to 20; or a pharmaceutically acceptable salt thereof; and ii) a phospholipid as described herein.
  • the lipid disorder is selected from coronary artery disease, rheumatoid arthritis, systemic lupus, diabetes, Alzheimer's disease, peripheral artery disease (PAD), diabetes-derived cardiovascular diseases, macular degeneration, and congestive heart failure.
  • the disclosed synthetic apolipoprotein E (ApoE)-mimicking peptides are
  • administering in an amount of about 0.01 mg/kg to about 20 mg/kg, e.g., 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 mg/kg, or any range in between.
  • Also disclosed are methods of treating acute coronary syndrome (ACS) comprising administering to a subject in need thereof i) a synthetic apolipoprotein E(ApoE)- mimicking peptide having the formula CH 3 (CH 2 ) x C(0)-LRRLRRRLLR- DWLKAFYDKVAEKLKEAF-NH 2 , wherein x is an integer from 1 to 20; or a
  • the disclosed synthetic apolipoprotein E (ApoE)- mimicking peptides are administered in an amount of about 0.01 mg/kg to about 20 mg/kg, e.g., 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 mg/kg, or any range in between.
  • compositions described herein can vary depending on many factors, such as but not limited to, age, condition, sex and extent of the disease in the patient, route of administration, length of treatment cycle, or whether other drugs are included in the regimen, and can be determined by one of skill in the art.
  • Effective dosages can be determined empirically, and making such determinations is within the skill in the art.
  • the dosage ranges for the administration of the compositions are those large enough to produce the desired effect in which the disease is treated.
  • the dosage can be an amount effective to provide therapeutic effects and provide or allow for sustained therapeutic effects even after the treatment is withdrawn.
  • the therapeutic effects can be, but are not limited to, a reduction in atherosclerotic lesions, decrease in arterial stiffness, decrease in isolated systolic hypertension, increase in vasoresponsiveness or improvement in cardiac function.
  • the therapeutic effects can be measured by markers of arterial inflammation such as, but not limited to, C-reactive protein.
  • the therapeutic effects can be measured by atherosclerosis imaging techniques, including MRI, intravascular ultrasound, ultrafast imaging CT scans, B-mode ultrasonography, virtual histology intravascular ultrasound, optical coherence tomography, or other known methods.
  • the dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like.
  • the dosage can be adjusted by the individual physician in the event of any counter-indications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
  • any suitable route of administration can be used for the disclosed compositions.
  • Suitable routes of administration can, for example, include topical, enteral, local, systemic, or parenteral.
  • administration can be
  • compositions can be used in and with any other therapy.
  • compositions are aqueous formulations that exists in e.g., H 2 0 (e.g, water for injection (WFI)), PBS (e.g., sterile PBS), and the like.
  • H 2 0 e.g, water for injection (WFI)
  • PBS e.g., sterile PBS
  • the foregoing formulations and administration methods are intended to be illustrative and not limiting. It will be appreciated that, using the teaching provided herein, other suitable formulations and modes of administration can be readily devised.
  • AEM-28, AEM-28-08 and AEM-28-14 were prepared according to the procedures described in U.S. Patent No. 6,506,880 and U.S. Provisional No. 62/031,585, and following standard solid-phase synthetic procedures.
  • AEM-28 was found to readily dissolve in 0.9% saline, while AEM-28-08 and AEM-28-14 formed suspensions with rapid settling. To overcome this obstacle, the polyethylene sorbitan ester Tween was added. The addition of Tween to AEM-28-08 and AEM-28-14 was found to not only dissolve the peptides, but also formed small, uniform micelles, thereby producing smaller, more consistent API containing particles. Table 1 shows results from this study.
  • Table 1A shows the correlation between the molar ratio of AEM-28- 14/poly ethylene sorbitan ester and particle size. No visible particles were seen.
  • the dose formulations for Groups 1-5 were formulated with Tween® 80 in PBS IX.
  • the dose formulation for Group 6 was formulated with Tween® 20 in PBS IX. All formulations for Sessions 1 and 2 were clear colorless solutions at the time of intravenous dose administration. Following dosing of each session, the residual dose formulations were stored -20 + 5°C until final disposition.
  • a total of thirty nine naive female CD-I mice were received from Charles River Laboratories, guitarist, NY. Following an acclimation period, the animals were assigned to the study based on acceptable health as determined by a staff veterinarian. Animals were placed into 6 groups (3 groups per session) for intravenous dose administration. Animal fasting was not required for this study. The final study design is presented in Table 3.
  • Each animal in Sessions 1 and 2 received a single intravenous dose of prepared test article at the target dose levels and dose volumes indicated in the table above. Animals were monitored continuously for any adverse clinical signs for the first hour following dose administration, at which point tolerability and dose escalation were assessed. In addition, clinical observations were performed for all animals at 2, 3, 4, 5, 6, 7 and 24 hours post-dose. A summary of clinical observations are as follows.
  • AEM-28-08 and AEM-28- 14 in 5% Tween® 80/PBS generated a NOAEL up to 15 mg/kg, with minimal effects observed at 25 mg/kg.
  • both AEM-28-08 and AEM-28-14 elicit significant reductions in cholesterol levels with AEM-28-14 essentially removing all circulating cholesterol for at least 6 hours post-dose. See e.g., FIG. 1A for total cholesterol levels and Figure IB where AEM-28-08 and AEM-28-14 each elicit a dramatic reduction in % change of total cholesterol at 4 mg/kg (to 9% and 2% of baseline). This reduction is superior to AEM-28, which exhibited a % change of total cholesterol to 38% of baseline. See e.g., FIG. IB.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions aqueuses comprenant un mélange de peptides synthétiques mimétiques de l'apolipoprotéine E (ApoE) et d'un ester de polyéthylène sorbitane, et leur utilisation pour réduire le taux de cholestérol plasmatique.
PCT/US2017/041663 2017-04-13 2017-07-12 Compositions de peptides mimétiques de l'apoe WO2018190896A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485165P 2017-04-13 2017-04-13
US62/485,165 2017-04-13

Publications (1)

Publication Number Publication Date
WO2018190896A1 true WO2018190896A1 (fr) 2018-10-18

Family

ID=59523225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/041663 WO2018190896A1 (fr) 2017-04-13 2017-07-12 Compositions de peptides mimétiques de l'apoe

Country Status (1)

Country Link
WO (1) WO2018190896A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
WO2007078879A2 (fr) * 2005-12-21 2007-07-12 Vaxinnate Corporation Compositions de lipopeptides et leurs procédés d'utilisation
WO2008021088A2 (fr) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Les salicylanilides renforcent l'administration par voie orale de peptides thérapeutiques
WO2009032702A2 (fr) 2007-08-28 2009-03-12 Uab Research Foundation Polypeptides synthétiques analogues d'apolipoprotéine e et procédés d'utilisation
WO2012047930A2 (fr) * 2010-10-04 2012-04-12 The Regents Of The University Of California Compositions et procédés de traitement de cancers gynécologiques
WO2013033260A1 (fr) * 2011-08-29 2013-03-07 The Regents Of The University Of California Utilisation de molécules associées au hdl pour traiter et prévenir des états pro-inflammatoires
WO2016018665A1 (fr) 2014-07-31 2016-02-04 Uab Research Foundation Peptides e-mimétiques d'apo ayant une puissance supérieure afin de dégager le taux de cholestérol plasmatique
WO2017120568A1 (fr) * 2016-01-08 2017-07-13 Lipimetix Development, Inc. Compositions de peptides mimétiques de l'apoe

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
WO2007078879A2 (fr) * 2005-12-21 2007-07-12 Vaxinnate Corporation Compositions de lipopeptides et leurs procédés d'utilisation
WO2008021088A2 (fr) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Les salicylanilides renforcent l'administration par voie orale de peptides thérapeutiques
WO2009032702A2 (fr) 2007-08-28 2009-03-12 Uab Research Foundation Polypeptides synthétiques analogues d'apolipoprotéine e et procédés d'utilisation
WO2012047930A2 (fr) * 2010-10-04 2012-04-12 The Regents Of The University Of California Compositions et procédés de traitement de cancers gynécologiques
WO2013033260A1 (fr) * 2011-08-29 2013-03-07 The Regents Of The University Of California Utilisation de molécules associées au hdl pour traiter et prévenir des états pro-inflammatoires
WO2016018665A1 (fr) 2014-07-31 2016-02-04 Uab Research Foundation Peptides e-mimétiques d'apo ayant une puissance supérieure afin de dégager le taux de cholestérol plasmatique
WO2017120568A1 (fr) * 2016-01-08 2017-07-13 Lipimetix Development, Inc. Compositions de peptides mimétiques de l'apoe

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences, 18th ed.,", 1990, MACK PUBLISHING COMPANY, pages: 1445
BRIAN J. VAN LENTEN ET AL: "Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits", JOURNAL OF LIPID RESEARCH, vol. 48, no. 11, 10 August 2007 (2007-08-10), US, pages 2344 - 2353, XP055429721, ISSN: 0022-2275, DOI: 10.1194/jlr.M700138-JLR200 *
C ROGER WHITE ET AL: "Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review", JOURNAL OF LIPID RESEARCH, 1 October 2014 (2014-10-01), United States, pages 2007 - 2021, XP055225410, Retrieved from the Internet <URL:http://www.jlr.org/content/55/10/2007.full.pdf#page=1&view=FitH> [retrieved on 20151103], DOI: 10.1194/jlr.R051367 *
GEETA DATTA ET AL: "The Receptor Binding Domain of Apolipoprotein E, Linked to a Model Class A Amphipathic Helix, Enhances Internalization and Degradation of LDL by Fibroblasts", BIOCHEMI, AMERICAN CHEMICAL SOCIETY, US, vol. 39, no. 1, 11 January 2000 (2000-01-11), pages 213 - 220, XP009135659, ISSN: 0006-2960, [retrieved on 19991211], DOI: 10.1021/BI991209W *
GODFREY S. GETZ ET AL: "Biological Properties of Apolipoprotein A-I Mimetic Peptides", CURRENT ATHEROSCLEROSIS REPORTS, vol. 12, no. 2, 20 February 2010 (2010-02-20), US, pages 96 - 104, XP055429633, ISSN: 1523-3804, DOI: 10.1007/s11883-010-0097-4 *
MAHLEY, R. W., SCIENCE, vol. 240, 1988, pages 622 - 630
SHIMONO, H. N. ET AL., EUR. J. CLIN. INVEST., vol. 90, 1992, pages 2084 - 2991
SPANGENBERG, J. ET AL., BIOCHEM. BIOPHYS. ACTA, vol. 1349, 1997, pages 109 - 121
SYLVIA WAGNER ET AL: "Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier Model", PLOS ONE, vol. 7, no. 3, 1 March 2012 (2012-03-01), pages e32568, XP055429615, DOI: 10.1371/journal.pone.0032568 *
YAMADA ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 86, 1989, pages 665 - 669
ZHANG, S. H. ET AL., SCIENCE, vol. 258, 1992, pages 468 - 471

Similar Documents

Publication Publication Date Title
US11801282B2 (en) Charged lipoprotein complexes and their uses
CA2486127C (fr) Methode de traitement de troubles dyslipidemiques
US20180203025A1 (en) Hdl therapy markers
JP2008534487A5 (fr)
KR101413361B1 (ko) 그람-양성 박테리아에 의해 유발되는 질병의 치료 또는예방 방법
WO2017120568A1 (fr) Compositions de peptides mimétiques de l&#39;apoe
CA2830664A1 (fr) Particule pegylee d&#39;hdl humaine et procede pour la production de celle-ci
WO2018190896A1 (fr) Compositions de peptides mimétiques de l&#39;apoe
WO2019199976A1 (fr) Compositions peptidiques mimétiques d&#39;apoe
Kim Optimization of synthetic high-density lipoprotein nanostructures for treatment of inflammatory diseases
AU2012202223B2 (en) Charged lipoprotein complexes and their uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17748968

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17748968

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载